Author
Listed:
- Ryan H. Gumpper
(University of North Carolina at Chapel Hill School of Medicine
University of North Carolina)
- Manish K. Jain
(University of North Carolina at Chapel Hill School of Medicine)
- Kuglae Kim
(Yonsei University)
- Renhong Sun
(Icahn School of Medicine at Mount Sinai)
- Ning Sun
(Icahn School of Medicine at Mount Sinai)
- Zhongli Xu
(Icahn School of Medicine at Mount Sinai)
- Jeffrey F. DiBerto
(University of North Carolina at Chapel Hill School of Medicine
LLC)
- Brian E. Krumm
(University of North Carolina at Chapel Hill School of Medicine)
- Nicholas J. Kapolka
(LLC)
- H. Ümit Kaniskan
(Icahn School of Medicine at Mount Sinai)
- David E. Nichols
(University of North Carolina)
- Jian Jin
(Icahn School of Medicine at Mount Sinai)
- Jonathan F. Fay
(University of Maryland Baltimore)
- Bryan L. Roth
(University of North Carolina at Chapel Hill School of Medicine
University of North Carolina)
Abstract
There is currently a resurgence in exploring the utility of classical psychedelics to treat depression, addiction, anxiety disorders, cluster headaches, and many other neuropsychiatric disorders. A biological target of these compounds, and a hypothesized target for their therapeutic actions, is the 5-HT2A serotonin receptor. Here, we present 7 cryo-EM structures covering all major compound classes of psychedelic and non-psychedelic agonists, including a β-arrestin-biased compound RS130-180. Identifying the molecular interactions between various psychedelics and the 5-HT2A receptor reveals both common and distinct motifs among the examined psychedelic chemotypes. These findings lead to a broader mechanistic understanding of 5-HT2A activation, which can catalyze the development of novel chemotypes with potential therapeutic utility and fewer side effects.
Suggested Citation
Ryan H. Gumpper & Manish K. Jain & Kuglae Kim & Renhong Sun & Ning Sun & Zhongli Xu & Jeffrey F. DiBerto & Brian E. Krumm & Nicholas J. Kapolka & H. Ümit Kaniskan & David E. Nichols & Jian Jin & Jonat, 2025.
"The structural diversity of psychedelic drug actions revealed,"
Nature Communications, Nature, vol. 16(1), pages 1-13, December.
Handle:
RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57956-7
DOI: 10.1038/s41467-025-57956-7
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-57956-7. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.